Cerus (CERS) said Wednesday its new LED-based illumination device INT200 has received CE mark approval under the European Union Medical Device Regulation.
The approval allows the company to market the INT200 for use with the Intercept Blood System for platelets and plasma throughout the European Union and other regions that recognize the CE mark, although some countries may still require additional local regulatory clearances, Cerus said.
The approval of the illuminator completes the authorization for the Intercept Blood System for both platelets and plasma as the platelet and plasma processing sets received CE mark approvals in 2023, according to the company.
Cerus said future improvements to the Intercept systems will use the INT200 device.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.